EMGALITY Drug Insight

“EMGALITY Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about EMGALITY for chronic pain in the seven major markets. A detailed picture of the EMGALITY for chronic pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the EMGALITY for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EMGALITY market forecast analysis for chronic pain in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

EMGALITY (galcanezumab) selectively binds to and neutralizes calcitonin gene-related peptide (CGRP); Eli Lilly develops it as an SC formulation for the preventive treatment of migraine and cluster headaches. CGRP is a potent vasodilatory neuropeptide widely distributed in the central and peripheral nervous systems. Involved in nociceptive transmission and modulation, CGRP has been firmly implicated in the pathophysiology of migraine and has recently emerged as a therapeutic target for the prophylaxis of migraine and related conditions.

Dosage and administration

It is available for SC use only.

• Recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg
• Administer the abdomen, thigh, back of the upper arm, or buttocks subcutaneously.
• Dosage forms and strengths
• It is available in two dosage forms
• Injection: 120 mg/mL solution in a single-dose prefilled pen
• Injection: 120 mg/mL solution in a single-dose prefilled syringe.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the EMGALITY description, mechanism of action, dosage and administration, research and development activities in chronic pain.
• Elaborated details on EMGALITY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EMGALITY research and development activities in chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EMGALITY.
• The report contains forecasted sales of for chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic pain.
• The report also features the SWOT analysis with analyst views for EMGALITY in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EMGALITY Analytical Perspective by DelveInsight

• In-depth EMGALITY Market Assessment

This report provides a detailed market assessment of EMGALITY for chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• EMGALITY Clinical Assessment

The report provides the clinical trials information of EMGALITY for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EMGALITY dominance.
• Other emerging products for chronic pain are expected to give tough market competition to EMGALITY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EMGALITY in chronic pain.
• Our in-depth analysis of the forecasted sales data of EMGALITY from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EMGALITY in chronic pain.
•  

Key Questions

• What is the product type, route of administration and mechanism of action of EMGALITY?
• What is the clinical trial status of the study related to EMGALITY in chronic pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EMGALITY development?
• What are the key designations that have been granted to EMGALITY for chronic pain?
• What is the forecasted market scenario of EMGALITY for chronic pain?
• What are the forecasted sales of EMGALITY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to EMGALITY for chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of chronic pain?